MO HB1072

Allows manufacturers and physicians to market investigational drugs, biological products, or devices to eligible terminally ill patients who are considering informed consent for label-expansion, placebo-controlled trials

Requires manufacturers or physicians seeking informed consent for placebo-controlled trials to either make the investigational treatment available outside the trial or provide contact information for physicians willing to prescribe it outside the trial

Establishes a $100,000 fine per patient for manufacturers who violate the marketing and access requirements

Creates the "Investigational Drug Fund" in the state treasury, funded by violation fines and lawsuit settlements related to off-label marketing, to cover costs for eligible patients whose insurance does not cover off-label use

Defines eligible patients as those with terminal illness who have considered FDA-approved treatments and relevant clinical trials, received a physician recommendation, and provided written informed consent